Heart Failure: Optimizing Medical Therapy and Patient Communication


CME Activity References

  1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137(12):e67-e492.

  2. Kilgore M, Patel HK, Kielhorn A, et al. Economic burden of hospitalizations of Medicare beneficiaries with heart failure. Risk Manag Healthc Policy. 2017;10:63-70.

  3. Borlaug BA. Moving Beyond Cardio-Centricity in Heart Failure Risk Stratification. Circulation. 2015;132(17):1602-1603.

  4. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-e327.

  5. Komanduri S, Jadhao Y, Guduru SS, et al. Prevalence and risk factors of heart failure in the USA: NHANES 2013 – 2014 epidemiological follow-up study. J Community Hosp Intern Med Perspect. 2017;7(1):15-20.

  6. Messerli FH, Rimoldi SF, Bangalore S. The Transition From Hypertension to Heart Failure. Contemporary Update. 2017;5(8):543-551.

  7. Mody P, Gupta A, Bikdeli B, et al. Most Important Articles on Cardiovascular Disease Among Racial and Ethnic Minorities. Circ Cardiovasc Qual Outcomes. 2012;5(4):e33-e41.

  8. Franciosa JA, Ferdinand KC, Yancy CW. Treatment of Heart Failure in African Americans: A Consensus Statement. Congest Heart Fail. 2010;16(1):27-38.

  9. Thomas KL, Hernandez AF, Dai D, et al. Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure. Am Heart J. 2011;161(4):746-754.

  10. Melero-Ferrer JL, López-Vilella R, Morillas-Climent H, et al. Novel Imaging Techniques for Heart Failure. Cardiac Fail Rev. 2016;2(1):27-34.

  11. Gaggin HK, Januzzi Jr JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832(12):2442-2450.

  12. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137-e161.

  13. Wettersten N, Maisel AS. Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine. Am J Med. 2016;129(6):560-567.

  14. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol. 2016;1(5):510-518.

  15. Borlaug BA, Redfield MM. Diastolic and Systolic Heart Failure are Distinct Phenotypes of the Heart Failure Syndrome. Circulation. 2011;123(18):2006-2014.

  16. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2014;370(15):1383-1392.

  17. Stewart D, McPherson ML. Symptom management challenges in heart failure: pharmacotherapy considerations. Heart Fail Rev. 2017;22(5):525-534.

  18. Alpert CM, Smith MA, Hummel SL, et al. Symptom burden in heart failure: assessment, impact on outcomes, and management. Heart Fail Rev. 2017;22(1):25-39.

  19. Heart Failure: An ACC Toolkit. Symptom and Activity Level Assessment.

  20. Yap J, Lim FY, Gao F, et al. Correlation of the New York Heart Association Classification and the 6-Minute Walk Distance: A Systematic Review. Clin Cardiol. 2015;38(10):621-628.

  21. Malhotra R, Bakken K, D’Elia E, et al. Cardiopulmonary Exercise Testing in Heart Failure. JACC Heart Fail. 2016;4(8):607-616.

  22. Kaiser DW, Harrington RA, Turakhia MP. Wearable Fitness Trackers and Heart Disease. JAMA Cardiol. 2016;1(2):239-239.

  23. Mangi MA, Rehman H, Rafique M, et al. Ambulatory Heart Failure Monitoring: A Systemic Review. Cureus. 2017;9(4):e1174.

  24. Ivynian SE, DiGiacomo M, Newton PJ. Care-seeking decisions for worsening symptoms in heart failure: a qualitative metasynthesis. Heart Fail Rev. 2015;20(6):655-671.

  25. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80(5):437-441.

  26. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureThe Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200.

  27. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.

  28. The Sprint Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116.

  29. MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure. An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377-1385.

  30. Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin a1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: An analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (charm) program. Arch Intern Med. 2008;168(15):1699-1704.

  31. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37(19):1526-1534.

  32. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317-1326.

  33. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322.

  34. Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial. JAMA. 2016;316(5):500-508.

  35. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128.

  36. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657.

  37. Radholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018.

  38. Kosiborod M, Cavender MA, Fu AZ, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136(3):249-259.

  39. Staels B. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. Am J Med. 2017;130(6):S30-S39.

  40. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134(13):e282-293.

  41. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993-1004.

  42. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2014;370(15):1383-1392.

  43. Taylor AL, Ziesche S, Yancy C, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. N Engl J Med. 2004;351(20):2049-2057.

  44. Taylor AL. The African American Heart Failure Trial: A Clinical Trial Update. Am J Cardiol. 2005;96(7):44-48.

  45. Exner DV, Dries DL, Domanski MJ, et al. Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction. N Engl J Med. 2001;344(18):1351-1357.

  46. Sharma A, Colvin-Adams M, Yancy CW. Heart failure in African Americans: Disparities can be overcome. Cleve Clin J Med. 2014;81(5):301-311.

  47. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med. 2015;373(12):1095-1105.

  48. Djoussé L, Gaziano JM. Alcohol Consumption and Heart Failure: A Systematic Review. Curr Atheroscler Rep. 2008;10(2):117-120.

  49. Anker SD, Comin Colet J, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361(25):2436-2448.

  50. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency(). Eur Heart J. 2015;36(11):657-668.

  51. Barlera S, Tavazzi L, Franzosi MG, et al. Predictors of Mortality in 6975 Patients with Chronic Heart Failure in the GISSI-HF Trial: Proposal for a Nomogram. Circ Heart Fail. 2012.

  52. Desai AS, Stevenson LW. Rehospitalization for Heart Failure. Predict or Prevent? Circulation. 2012;126(4):501-506.

  53. Eapen ZJ, Liang L, Fonarow GC, et al. Validated, Electronic Health Record Deployable Prediction Models for Assessing Patient Risk of 30-Day Rehospitalization and Mortality in Older Heart Failure Patients. JACC Heart Fail. 2013;1(3):245-251.

  54. Watson AJ, O’Rourke J, Jethwani K, et al. Linking electronic health record-extracted psychosocial data in real-time to risk of readmission for heart failure. Psychosomatics. 2011;52(4):319-327.

  55. Philbin EF, Dec GW, Jenkins PL, et al. Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol. 2001;87(12):1367-1371.

  56. Breathett K, Liu WG, Allen LA, et al. African Americans Are Less Likely to Receive Care by a Cardiologist During an Intensive Care Unit Admission for Heart Failure. JACC Heart Fail. 2018;6(5):413-420.

  57. Mitchell JE, Ferdinand KC, Watson KE, et al. Treatment of Heart Failure in African Americans— A Call to Action. J Natl Med Assoc. 2011;103(2):86-98.

  58. Bradley EH, Curry L, Horwitz LI, et al. Hospital Strategies Associated With 30-Day Readmission Rates for Patients With Heart Failure. Circ Cardiovasc Qual Outcomes. 2013;6(4):444-450.

  59. Dunbar-Yaffe R, Stitt A, Lee JJ, et al. Assessing Risk and Preventing 30-Day Readmissions in Decompensated Heart Failure: Opportunity to Intervene? Curr Heart Fail Rep. 2015;12:309-317.

  60. Target: HF Strategies and Clinical Tools.

http://www.heart.org/HEARTORG/Professional/TargetHFStroke/TargetHF/Target-HF-Strategies-and-Clinical-Tools_UCM_432444_Article.jsp. Accessed October 29, 2017.

ABOUT FIGURE 1
LEGAL
HOW  FIGURE 1 WORKS
PRESS